Ayahuasca and Addiction: Evidence, Detox Risks and Relapse Planning

Interest in ayahuasca addiction treatment has grown faster than the clinical evidence. Observational studies describe reduced alcohol or drug use after ceremonial participation, and laboratory research suggests possible mechanisms. Those signals deserve study, but they do not establish ayahuasca as an approved treatment, a safe detox method or a substitute for continuing addiction care.

“Addiction” also covers very different conditions. Alcohol, opioids, stimulants, cannabis, nicotine, sedatives and mixed substance use have different withdrawal risks, medications and overdose patterns. A person who is medically stable in long-term recovery is not in the same situation as someone arriving intoxicated, withdrawing or at high risk of overdose.

What the ayahuasca and addiction evidence actually shows

A 2022 systematic review identified nine newer studies: four preclinical experiments and five observational human studies. Animal work reported changes in alcohol- and stimulant-related behavior. Human studies described lower substance use and improvements in anxiety, depression or wellbeing among ritual users and people with substance use disorders.

The authors also identified the central limits. Animal findings do not prove a human treatment effect. Observational studies cannot show that ayahuasca caused the outcome, because participants choose the setting and may differ from people who do not attend. Doses, brews, support and follow-up were not standardized. Randomized controlled trials were still needed.

A 2025 systematic review covering multiple psychedelic-assisted approaches included only three ayahuasca studies with 101 participants. The review judged that the strongest evidence for alcohol use disorder came from psilocybin—not ayahuasca. Evidence from another psychedelic cannot be transferred to a commercial ayahuasca retreat.

The 11-person alcohol study was a feasibility test

The first prospective human trial specifically assessing alcohol outcomes gave one ayahuasca dose with psychological support to 11 college students reporting harmful alcohol use. It was single-center and single-blind, with no placebo control. The study was designed mainly to determine whether the protocol was feasible.

Days of alcohol use appeared lower between weeks two and three, but the result was no longer statistically significant after Bonferroni correction for multiple comparisons. Other alcohol and clinical outcomes were not significantly different. The participants also began with mild to moderate harmful use, so the study does not establish safety or effectiveness for severe alcohol dependence.

A feasibility signal can justify a larger controlled trial. It cannot support a promise that one ceremony treats alcohol use disorder, prevents relapse or replaces evidence-based care.

Why observational improvements are hard to interpret

People who seek a retreat may already be highly motivated to change. Travel can temporarily remove access to a substance, familiar cues and social contacts. Group support, expectancy, sleep, food, structured days and the decision to spend money on recovery can all influence behavior. Participants who improve may be more likely to answer follow-up surveys.

Ritual-user comparisons also cannot determine whether ayahuasca, community membership, abstinence rules or other lifestyle differences produced lower addiction scores. Self-reported reductions are meaningful to study, but they are not equivalent to verified abstinence, reduced overdose, sustained remission or improved survival.

A 2026 review of prospective ayahuasca studies found preliminary changes in substance misuse and wellbeing, while emphasizing small samples, nonrandomized designs, unstandardized doses and retreat volunteers. Some participants also reported persistent psychiatric complications.

Craving is only one part of recovery

A systematic review of psychedelics and craving included 31 studies and 2,639 participants across alcohol, opioid, cocaine and tobacco disorders. Twelve studies reported significant craving reductions, but nearly all had methodological problems and the overall risk of bias was moderate to high.

Even a genuine short-term reduction in craving would not automatically repair tolerance, housing, trauma, liver disease, infectious disease, legal stress, relationships or access to treatment. Recovery outcomes should include substance use, overdose, functioning, mental health, retention in care and quality of life over meaningful follow-up.

A retreat is not medical detox

Detoxification is the clinical management of intoxication and withdrawal. It may require repeated assessment, medication, vital-sign monitoring, laboratory tests or hospital transfer. A remote lodge should not advertise ceremonies as a way to “flush out” alcohol, opioids, benzodiazepines or stimulants.

Purging does not accelerate recovery from dependence. Vomiting and diarrhea can worsen dehydration, electrolyte disturbance and medication absorption. Read our guide to ayahuasca purging and emergency warning signs.

A person who is intoxicated, medically unstable or actively withdrawing should not proceed to ceremony. Stabilization and an appropriate level of addiction treatment come first.

Alcohol withdrawal can be life-threatening

The US National Institute on Alcohol Abuse and Alcoholism warns that sudden cessation after prolonged heavy drinking can produce potentially life-threatening withdrawal. Symptoms may include tremor, sweating, increased pulse and blood pressure, insomnia, anxiety, vomiting, seizures and delirium tremens.

Risk depends on recent use, previous withdrawal seizures or delirium, other sedatives, medical conditions and current symptoms. Some people can be managed in structured outpatient detox; others require intensive inpatient monitoring. That decision belongs to qualified clinicians with access to emergency care.

Detox is only an initial step. NIAAA notes that continuing alcohol treatment is measured in months or years, not the few days required to manage acute withdrawal.

Benzodiazepines should not be stopped for a booking

Alprazolam, clonazepam, diazepam, lorazepam and related medicines can produce physical dependence even when prescribed. The 2025 joint clinical guideline led by the American Society of Addiction Medicine advises that patients taking benzodiazepines regularly for more than a month should not abruptly discontinue them.

Severe withdrawal can include confusion, delirium, psychosis, suicidality and seizures. A retreat washout rule cannot replace a clinician-guided taper. Physical dependence is also not automatically the same as addiction; stigmatizing prescribed use can push someone toward unsafe discontinuation.

Protect medications for opioid and alcohol use disorders

Buprenorphine, methadone and naltrexone are evidence-based medications for opioid use disorder. Medications are also available for alcohol and tobacco use disorders. SAMHSA advises people to consult their clinician before discontinuing treatment; these medicines are not simply replacing one addiction with another.

A retreat should never require someone to conceal or abandon prescribed addiction medication. Any medication decision needs the exact drug, formulation, dose, timing, liver and heart history, other prescriptions and relapse risk. Ayahuasca contains beta-carbolines that inhibit monoamine oxidase A, creating additional interaction questions.

Medication review may also involve antidepressants, stimulants, sleep medicines, pain medicines and psychiatric treatment. See our detailed guide to ayahuasca and antidepressant interactions.

Screen the whole pattern, not a substance label

Responsible screening should document:

• every substance used, amount, route, frequency and most recent use;
• past overdose, blackouts, withdrawal seizures or delirium;
• current intoxication, withdrawal, craving and ability to remain safe;
• prescribed, nonprescribed and over-the-counter medicines;
• previous treatment, medication, recovery supports and relapse pattern;
• depression, anxiety, trauma, mania, psychosis and suicidal risk;
• heart, liver, kidney, neurological, metabolic and infectious conditions;
• pregnancy and breastfeeding; and
• who can provide collateral information and urgent support.

Polysubstance use is common. Someone may understate sleeping pills, stimulants or pain medicines because they do not consider them “drugs.” Screening questions must be specific, confidential and nonpunitive.

Co-occurring mental health risks change the plan

Substance use may coexist with depression, panic, PTSD, bipolar disorder, psychosis or suicidal thinking. Symptoms may worsen during intoxication, withdrawal, sleep loss or medication changes. A ceremony cannot determine which condition is driving the crisis.

Current suicidal intent, inability to stay safe, severe agitation, mania or psychosis needs urgent clinical care. Review our guides to ayahuasca and depression, PTSD and trauma-informed screening, and bipolar disorder, mania and psychosis.

Build continuity of care before travel

Discuss the proposed retreat with the clinician or addiction team that knows the history. Share the destination, travel time, ceremony schedule, medication policy and actual emergency resources. A remote retreat should not be the first place that learns about recent overdose, severe withdrawal or unstable housing.

A written plan should identify who manages prescriptions, how daily dosing continues, who holds emergency information, when further ceremonies stop, where medical transfer occurs and when follow-up is scheduled. If the treating team advises postponement, a prepaid booking should not overrule that decision.

Travel insurance may exclude substance-related events, pre-existing conditions or planned psychoactive use. Review the wording using our retreat travel insurance guide.

Plan for relapse and overdose risk after travel

Time away from a substance can lower tolerance. Returning to a previously used amount can therefore increase overdose risk, particularly with opioids and mixed sedatives. A powerful ceremony does not make someone immune to cues, stress, availability or withdrawal.

Before travel, create a response for craving, lapse and relapse. Keep treatment contacts active, arrange rapid re-entry to care, identify a trusted person, protect medication access and follow local clinical guidance on overdose prevention. Do not frame a lapse as moral failure or proof that the ceremony “did not work.”

Relapse signals a need to reassess and adjust support. Shame and secrecy can delay lifesaving care.

Follow-up should measure behavior, safety and function

Book follow-up before departure. Review substance use, craving, sleep, mood, medication adherence, overdose risk, work, housing, relationships and engagement in treatment. Record both improvement and deterioration instead of treating every difficult response as spiritual progress.

Integration may help someone reflect on an experience, but it is not a substitute for licensed addiction treatment. A facilitator should not diagnose remission, direct a taper or discourage contact with clinicians, medication programs or mutual-support groups.

Urgent warning signs need ordinary emergency care

Seek urgent medical help for seizure, severe confusion, hallucinations, chest pain, breathing difficulty, fainting, very high fever, persistent vomiting, reduced consciousness, suspected overdose, uncontrolled agitation or inability to maintain safety. Do not leave the person alone or give another psychoactive substance to counteract symptoms.

Share the substances used, approximate timing, prescribed medicines, ayahuasca exposure and relevant medical history with emergency clinicians. Retreat staff should activate their transfer plan rather than attempting prolonged management of withdrawal or overdose in a remote setting.

Retreat claims that should make you pause

Be cautious when a provider:

• advertises ayahuasca as a proven cure for addiction;
• calls vomiting a substitute for detoxification;
• accepts guests who are intoxicated or in active withdrawal;
• requires abrupt discontinuation of methadone, buprenorphine or benzodiazepines;
• does not ask about overdose, withdrawal seizures or polysubstance use;
• has no sober overnight staff or emergency transfer process;
• discourages evidence-based medication or continuing care; or
• guarantees abstinence after one ceremony.

Compare providers with our guide to choosing a safer ayahuasca retreat in Peru.

Frequently asked questions

Is ayahuasca approved for addiction treatment?

No. Ayahuasca is not an approved treatment for alcohol, opioid, stimulant or other substance use disorders. Human research is preliminary.

Can an ayahuasca retreat replace rehab or detox?

No. Medical detox manages potentially dangerous withdrawal, while addiction treatment provides continuing medication, therapy and recovery support. A retreat does not replace either level of care.

What did the alcohol trial prove?

It showed that a small protocol involving 11 students was feasible. The apparent reduction in drinking days did not remain significant after statistical correction, so it did not prove effectiveness.

Should methadone or buprenorphine be stopped before ayahuasca?

Not without the treating clinician. These are evidence-based treatments, and stopping can increase withdrawal, relapse and overdose risk. A retreat should not prescribe discontinuation.

Can someone detox from alcohol at a retreat?

Not safely as a general retreat service. Alcohol withdrawal can cause seizures or delirium and may require monitored medical treatment.

Does ayahuasca itself cause addiction?

Available studies have not shown the compulsive use pattern typical of many addictive drugs, but that does not make it risk-free. Acute and persistent adverse effects, unsafe settings and repeated use without benefit remain possible.

Recovery needs more than one intense experience

Ayahuasca research offers hypotheses and preliminary signals—not a validated addiction treatment. The strongest responsible position is to protect proven care, prevent unsafe withdrawal, screen co-occurring conditions and build long-term follow-up before discussing a retreat.

Review Ayaterra’s ayahuasca retreats near Iquitos and contact the team for current screening requirements. Disclose substances, recent use, overdose history, withdrawal history, prescribed treatment and clinical recommendations before booking.

Research and health sources

• Systematic review of ayahuasca and substance use disorder studies
• Feasibility study of one ayahuasca dose in 11 students with harmful alcohol use
• Review of ayahuasca research for alcohol use disorder
• Systematic review of psychedelic-assisted treatments for substance use disorders
• Systematic review of psychedelics and craving
• 2026 systematic review of prospective long-term ayahuasca studies
• Global Ayahuasca Survey report on adverse effects
• NIAAA: alcohol use disorder, withdrawal and recovery
• SAMHSA: evidence-based treatment and medication options
• Joint clinical guideline on benzodiazepine tapering

Medical disclaimer: This article provides general education and does not diagnose a substance use disorder, recommend ayahuasca or determine personal retreat safety. Do not stop alcohol, benzodiazepines, opioids or prescribed treatment without qualified clinical guidance. Suspected overdose, severe withdrawal, seizure, delirium, suicidal intent or life-threatening symptoms require urgent local emergency care.